- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Seizures associated with Dravet Syndrome
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 186KB)
Fenfluramine – November 2024
Fenfluramine; Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL; Fintepla®
Last updated
30 May 2025